RT Journal Article SR Electronic T1 Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity JF Journal of Pharmacology and Experimental Therapeutics JO J Pharmacol Exp Ther FD American Society for Pharmacology and Experimental Therapeutics SP 300 OP 307 DO 10.1124/jpet.108.139162 VO 327 IS 2 A1 Man Jiang A1 Zheng Dong YR 2008 UL http://jpet.aspetjournals.org/content/327/2/300.abstract AB Cisplatin is one of the most potent chemotherapy drugs widely used for cancer treatment. However, its use is limited by side effects in normal tissues, particularly the kidneys. Recent studies, using both in vitro and in vivo experimental models, have suggested a critical role for p53 in cisplatin nephrotoxicity. The signaling pathways upstream and downstream of p53 are being investigated and related to renal cell injury and death. Along with the mechanistic studies, renoprotective approaches targeting p53 have been suggested. Further research may integrate p53 signaling with other nephrotoxic signaling pathways, providing a comprehensive understanding of cisplatin nephrotoxicity and leading to the development of effective renoprotective strategies during cancer therapy. The American Society for Pharmacology and Experimental Therapeutics